Advanced Search:
Equity Index Forex Crypto Commodity

INO - Inovio Pharmaceuticals

$11.03  -0.73 (-6.21%)

Updated: 03:10 May 5, 2024 EST

Next Hour's AI Forecast

98.45%

Avg. Accuracy (AI)

$10.86

Next Session's AI Forecast

93.43%

Avg. Accuracy (AI)

$11.17

Next Week's AI Forecast

100%

Trend's Accuracy (AI)

$11.41

Inovio Pharmaceuticals's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

INOVIO PHARMACEUTICALS - HISTORICAL DATA 6M

  • Last price

    $ 11.03

  • Daily change

    $ -0.73

  • Previous Close

    $ 11.76

  • Last Updated

    03:10 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
-2.55 -0.22 0.92 0.85 0.12

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
3.05 4.49 4.87 5.18 4.74

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
0% 37.91% 61.38% 62.86%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
11.34 2.44% 11.07 -3.15% 11.43 108.58% 5.48

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.63 40.12 1.36 38.65

Inovio Pharmaceuticals Technical Analysis News

Inovio Pharmaceuticals

660 West Germantown Pike
Suite 110
Plymouth Meeting, PA 19462
United States
267 440 4200
https://www.inovio.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 122
Description

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Corporate Governance

Inovio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 7. The pillar scores are Audit: 8; Board: 3; Shareholder Rights: 4; Compensation: 10.

INOVIO PHARMACEUTICALS'S HOLDERS RANK

List of holders with stock participation in Inovio Pharmaceuticals.

Holder Rank Holder Shares Date Reported % Out Value